论文部分内容阅读
<正>Unprecedented progress has seen made in the last decade in the fi eld of cancer immunotherapy.The recent approval of nivolumab(Opdivo),the fi rst anti-programmed cell death-1(PD-1)antibody,for metastatic melanoma in Japan,marked a milestone in th